Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Arisa Nishimukai"'
Autor:
Michiko Imamura, Takashi Morimoto, Takashi Nomura, Shintaro Michishita, Arisa Nishimukai, Tomoko Higuchi, Yukie Fujimoto, Yoshimasa Miyagawa, Ayako Kira, Keiko Murase, Kazuhiro Araki, Yuichi Takatsuka, Koshi Oh, Yoshikazu Masai, Kouhei Akazawa, Yasuo Miyoshi
Publikováno v:
World Journal of Surgical Oncology, Vol 16, Iss 1, Pp 1-11 (2018)
Abstract Background Although the prognosis for operable breast cancers is reportedly worse if serum carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) levels are above normal, the usefulness of this prognosis is limited due to the low se
Externí odkaz:
https://doaj.org/article/5a6e30eea34e484e8a64a217e128c415
Autor:
Arisa Nishimukai, Natsuko Inoue, Ayako Kira, Masashi Takeda, Koji Morimoto, Kazuhiro Araki, Kazuhiro Kitajima, Takahiro Watanabe, Seiichi Hirota, Toyomasa Katagiri, Shoji Nakamori, Kouhei Akazawa, Yasuo Miyoshi
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0184508 (2017)
It has been well established that maximum standardized uptake value (SUVmax) for 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG PET/CT) is clinically useful for evaluating treatment efficacy as well as predicting prognos
Externí odkaz:
https://doaj.org/article/320dcac5a0064097b5cc9291e0dd52e9
Publikováno v:
European Journal of Surgical Oncology. 49:e91
Autor:
Yasuo Miyoshi, Yoshimasa Miyagawa, Chiyomi Egawa, Atsushi Sata, Takehiro Yanagawa, Takashi Morimoto, Hiromi Ozawa, Ayako Bun, Kaori Takamoto, Yukie Fujimoto, Arisa Nishimukai, Tomoko Higuchi, Reiko Fukui, Jyunichi Inatome, Ayako Yanai, Michiko Imamura
Publikováno v:
Cancer Research. 80:P3-08
Background Vascular endothelial growth factor (VEGF) is a key player in angiogenesis, and bevacizumab, a humanized monoclonal antibody against VEGF-A, is already utilized in daily clinical practice coupled with chemotherapy for locally advanced and m
Autor:
Ai Yamaguchi, Michiko Imamura, Yuki Okada, Tomoe Taji, Arisa Nishimukai, Tomoko Higuchi, Ayako Yanai, Takashi Morimoto, Takehiro Yanagawa, Ayako Bun, Hirofumi Suwa, Yuichiro Kikawa, Yasuo Miyoshi, Yoshimasa Miyagawa, Atsushi Sata, Hiromi Ozawa, Chiyomi Egawa, Kaori Takamoto, Yukie Fujimoto, Reiko Fukui, Junichi Inatome
Publikováno v:
Oncotarget
The effect of bevacizumab plus paclitaxel therapy on progression-free survival (PFS) is prominent; however, no overall survival (OS) benefit has been demonstrated. Our aim was to study the predictive efficacy of peripheral immune-related parameters,
Publikováno v:
European Journal of Surgical Oncology. 48:e77
Autor:
Yoshimasa Miyagawa, Ayako Bun, Yukie Fujimoto, Tomoko Higuchi, Hiromi Ozawa, Michiko Imamura, Yuichi Takatsuka, Kazuhiro Araki, Ayako Kira, Yasuo Miyoshi, Arisa Nishimukai
Publikováno v:
Clinical Breast Cancer. 18:400-409
Although eribulin and nab-paclitaxel are chemotherapy agents widely used for locally advanced or metastatic breast cancer (MBC), their predictive factors remain unknown. Because the absolute neutrophil-to-lymphocyte ratio (NLR) is a significant progn
Autor:
Hiromi Ozawa, Ayako Bun, Yoshimasa Miyagawa, Ayako Kira, Yukie Fujimoto, Tomoko Higuchi, Arisa Nishimukai, Yasuo Miyoshi, Michiko Imamura
Publikováno v:
Journal of Surgical Oncology. 118:228-237
Background and objectives To identify surrogate markers for prognosis of breast cancer patients with non-pathological complete response (non-pCR) to neoadjuvant chemotherapy (NAC), our investigation focused on the serum levels of carcinoembryonic ant
Autor:
Yuichi Takatsuka, Yukie Fujimoto, Arisa Nishimukai, Michiko Imamura, Yasuo Miyoshi, Yoshimasa Miyagawa, Keiko Murase, Tomoko Higuchi, Ayako Yanai
Publikováno v:
Cancer Research. 77:P2-05
Background: It has been well demonstrated that patients who achieved pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) had a favorable prognosis compared with patients who did not (non-pCR). Even though pCR was not attained, r
Autor:
Yoshimasa Miyagawa, Keiko Murase, Arisa Nishimukai, Hiromi Ozawa, Tomoko Higuchi, Kazuhito Fukushima, Yukie Fujimoto, Ayako Yanai, Yasuo Miyoshi, Kazuhiro Kitajima, Michiko Imamura, Yuichi Takatsuka
Publikováno v:
The Breast. 30:5-12
Adjuvant treatments for operable breast cancers are determined according to subtypes defined based on estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status. The ER+/HER2− subtype can be divided into luminal A and luminal